$ENDP (Endo International plc)

$ENDP {{ '2016-08-08T22:40:42+0000' | timeago}} • Webcast

David Risinger of Morgan Stanley asks about BELBUCA sales. $ENDP said it has seen minimal revenue recognition from BELBUCA in 1H16 in the single digit level. Given the launch ramp expectations, the company expects the contribution in 2016 to be relatively modest. 2017 will be the first year of revenue contribution for BELBUCA.

$ENDP {{ '2017-07-21T14:56:21+0000' | timeago}} • Announcement

$ENDP said it will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama. The closure is expected to take place over the next 12 to 18 months. These restructuring actions are expected to reduce $ENDP's workforce by about 875 positions and to result in pre-tax restructuring charges of about $325MM.

$ENDP {{ '2017-07-06T17:01:40+0000' | timeago}} • Announcement

Following FDA's June 2017 withdrawal request, $ENDP has decided to voluntarily remove OPANA ER, a painkiller, from the market, to prevent its misuse.  As a result, $ENDP expects to incur a pre-tax impairment charge of approx $20MM in 2Q17. Reported net sales of OPANA ER were $158.9MM for FY16 and $35.7MM for 1Q17.

$ENDP {{ '2017-07-05T12:36:12+0000' | timeago}} • Announcement

$ENDP today announced it has entered into a definitive agreement to sell Mexico City-based Grupo Farmacéutico SOMAR to Advent International for approximately $124MM subject to customary adjustments for cash, debt and working capital.

$ENDP {{ '2017-07-03T18:36:53+0000' | timeago}} • Announcement

$ENDP completed the divestiture of its South African based operations, Litha Healthcare Group, to Acino Pharma AG. At closing, the company received approx. $100MM in cash and may receive up to an additional $11MM in contingent consideration.

$ENDP {{ '2017-05-09T14:06:41+0000' | timeago}} • Announcement

$ENDP now sees FY17 total revenues of $3.45-3.60Bil, generating a diluted GAAP loss from continuing operations of $0.80-0.50 per share. Adjusted EBITDA from continuing operations is estimated to be between $1.50Bil to $1.58Bil for the full year.

$ENDP {{ '2017-05-09T14:04:01+0000' | timeago}} • Announcement

$ENDP saw an 8% jump in revenues of $1.04Bil for 1Q17 but its net attributable loss widened to $173.8MM from last year's $133.9MM loss. Losses rose to $0.78 per diluted share from $0.60 a share, as reported loss from continuing operations bloated 86% to $165.4MM for the quarter.

$ENDP {{ '2017-04-10T18:18:21+0000' | timeago}} • Announcement

$ENDP said its subsidiaries Endo Designated Activity Co., Endo Finance LLC and Endo Finco Inc. (Issuers) plan to offer senior secured notes. $ENDP plans to use this proceeds, together with the proceeds of its new term loan facility and cash on hand, to repay all its outstanding loans and all other obligations under its existing credit facilities.

$ENDP {{ '2017-02-28T15:24:45+0000' | timeago}} • Webcast

With regards to the 2018 outlook, $ENDP said that it is focused on 2017 alone at this point. The company said that it will not be able to guide beyond 2017 because of the uncertainties in the business.

$ENDP {{ '2017-02-28T15:11:42+0000' | timeago}} • Webcast

$ENDP expects Litha Healthcare Group divestiture to close in 2Q17. About 53% of total enterprise revenue in 2017 is expected to be realized in 1H17. Gross margin percentage in 1Q17 to be broadly in line to slightly below 4Q16 with meaningful improvement during the course of the year. 1Q17 operating expenses are estimated to be largely in line with 4Q16.

$ENDP {{ '2017-02-28T15:03:42+0000' | timeago}} • Webcast

$ENDP's net loss was $3.3Bil in 4Q16, resulting from $3.5Bil goodwill and intangible asset impairment charges reported in the quarter. The company conducted its annual goodwill and in-process R&D impairment tests and tested several other intangible assets during the quarter.

$ENDP {{ '2017-02-28T14:57:15+0000' | timeago}} • Infographic

$ENDP Endo International Earnings AlphaGraphics: Q4 2016 Highlights

$ENDP {{ '2017-02-28T14:49:41+0000' | timeago}} • Webcast

In 2017, $ENDP expects US Branded Pharma segment revenue to decline in the low-to-mid teen percentage range year-over-year. Specialty business is expected to grow in the high-single digit.

$ENDP {{ '2017-02-28T14:34:19+0000' | timeago}} • Webcast

For 2017, $ENDP expects US Generics base business revenue decline to be similar to 2016 or in the low 30% range. Generics segment sales are expected to decline in the high-single to low-double digit range. In US Generics business, $ENDP estimates to realize approx. $75MM in annual net savings and launch at least 20 products in 2017.

$ENDP {{ '2017-02-28T14:00:48+0000' | timeago}} • Webcast

$ENDP, which divested its Belbuca business and restructured Pain franchise business in 4Q16, announced its plans to divest Litha Healthcare Group business for $100MM to Acino. The company has also identified Somar business as non-core and will be conducting due diligence on divesting Somar to focus on regulated markets in developed countries.

$ENDP {{ '2017-02-28T12:57:20+0000' | timeago}} • Announcement

For FY17, $ENDP expects total revenues to be in the range of $3.45-3.60Bil and diluted EPS from continuing operations to be between $0.04-0.34. The company anticipates adjusted diluted EPS from continuing operations to be between $3.45-3.75.

$ENDP {{ '2017-02-28T12:53:37+0000' | timeago}} • Announcement

During 4Q16, $ENDP's U.S. Generic Pharmaceuticals business unit revenue rose 45% to $882MM, due to launch of quetiapine extended-release tablets. Revenues of U.S. Branded Pharmaceuticals fell 24% to $289MM. International pharmaceuticals revenue fell 18% to $70MM.

$ENDP {{ '2017-02-28T12:48:50+0000' | timeago}} • Announcement

Pharmaceutical company $ENDP reported net loss of $3.33Bil, or $14.98 per share, compared to $118MM, or $0.53 per share during 4Q15. Total revenues rose 16% YoY to $1.24Bil, helped by launch of generic products. Excluding items, $ENDP earned $1.77 per share.

$ENDP {{ '2017-01-31T12:56:17+0000' | timeago}} • Announcement

$ENDP announced that one of its operating companies, Par Pharmaceutical has received final approval from the US Food and Drug Administration for its New Drug Application for ephedrine sulfate injection, a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings.

$ENDP {{ '2017-01-26T16:26:10+0000' | timeago}} • Announcement

$ENDP initiated a restructuring program. These actions will result in restructuring cash charges of about $15-20MM. $ENDP expects to realize about $40-50MM in annual run rate pre-tax cost savings by 4Q17. In addition to realizing greater efficiencies, these actions are expected to provide corresponding cost savings.

$ENDP {{ '2017-01-26T16:24:27+0000' | timeago}} • Announcement

$ENDP initiated a restructuring program as part of its comprehensive organizational review. These actions primarily relate to the company's Corporate functions and Branded pharmaceutical R&D functions in Malvern, PA and Chestnut Ridge, NY. These will reduce the company's work force by about 90 full-time positions.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
NKTR (Nektar Therapeutics)
Tuesday, May 9 2017 - 9:00pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
OSUR (OraSure Technologies, Inc.)
Wednesday, May 3 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
IDXX (IDEXX Laboratories, Inc.)
Friday, April 28 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, April 26 2017 - 12:30pm
BAX (Baxter International Inc.)
Wednesday, April 26 2017 - 12:30pm
LLY (Eli Lilly and Company)
Tuesday, April 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, April 25 2017 - 12:30pm

AlphaGraphics you may like